BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18566541)

  • 1. Leukemic cluster growth in culture is an independent risk factor for acute myeloid leukemia and short survival in patients with myelodysplastic syndrome.
    Bernimoulin M; Stern M; Tichelli A; Jotterand M; Gratwohl A; Nissen C
    Acta Haematol; 2008; 119(4):226-35. PubMed ID: 18566541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients.
    Aggerholm A; Holm MS; Guldberg P; Olesen LH; Hokland P
    Eur J Haematol; 2006 Jan; 76(1):23-32. PubMed ID: 16343268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
    Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
    Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic potential of morphological and cytogenetic indices in patients with myelodysplastic syndrome].
    Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Tiranova SA; Kakaĭ MP; Martynenko LS; Dziavgo LA
    Ter Arkh; 2005; 77(7):22-7. PubMed ID: 16116904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome.
    Wang H; Wang XQ; Xu XP; Lin GW
    Leuk Res; 2010 May; 34(5):598-604. PubMed ID: 19853913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia.
    Neumann F; Gattermann N; Barthelmes HU; Haas R; Germing U
    Leuk Res; 2009 Feb; 33(2):232-6. PubMed ID: 18639338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
    Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
    Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
    Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro growth modulation by L-ascorbic acid of colony-forming cells from bone marrow of patients with myelodysplastic syndromes.
    Park CH; Kimler BF; Bodensteiner D; Lynch SR; Hassanein RS
    Cancer Res; 1992 Aug; 52(16):4458-66. PubMed ID: 1643638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.
    Del Cañizo MC; Brufau A; Mota A; Lopez N; Fernandez ME; Vallejo C; Hernandez JM; Garcia JL; San Miguel JF
    Haematologica; 1998 Jan; 83(1):3-7. PubMed ID: 9580461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Hock BD; McKenzie JL; Patton WN; Haring LF; Yang Y; Shen Y; Estey EH; Albitar M
    Cancer; 2003 Oct; 98(8):1681-8. PubMed ID: 14534885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
    Swolin B; Rödjer S; Westin J
    Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
    Hu Q; Dey AL; Yang Y; Shen Y; Jilani IB; Estey EH; Kantarjian HM; Giles FJ; Albitar M
    Cancer; 2004 May; 100(9):1884-91. PubMed ID: 15112269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.
    Breccia M; Frustaci AM; Cannella L; Stefanizzi C; Latagliata R; Cartoni C; Diverio D; Guarini A; Nanni M; Rago A; Cimino G; Alimena G
    Hematol Oncol; 2009 Sep; 27(3):148-53. PubMed ID: 19274612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
    Della Porta MG; Malcovati L; Boveri E; Travaglino E; Pietra D; Pascutto C; Passamonti F; Invernizzi R; Castello A; Magrini U; Lazzarino M; Cazzola M
    J Clin Oncol; 2009 Feb; 27(5):754-62. PubMed ID: 19103730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
    Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
    Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
    Neukirchen J; Blum S; Kuendgen A; Strupp C; Aivado M; Haas R; Aul C; Gattermann N; Germing U
    Eur J Haematol; 2009 Nov; 83(5):477-82. PubMed ID: 19548919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndromes in patients under 50 years old: a single institution experience.
    Breccia M; Mengarelli A; Mancini M; Biondo F; Gentilini F; Latagliata R; Mandelli F; Alimena G
    Leuk Res; 2005 Jul; 29(7):749-54. PubMed ID: 15927670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database.
    Shukron O; Vainstein V; Kündgen A; Germing U; Agur Z
    Am J Hematol; 2012 Sep; 87(9):853-60. PubMed ID: 22674538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.